The O O O O
immune O O O O
system O O O O
functions O O O O
as O O O O
the O O O O
body's O O O O
police O O O O
force, O O O O
protecting O O O O
it O O O O
from O O O O
intruders O O O O
like O O O O
bacteria O O O O
and O O O O
viruses. O O O O
However, O O O O
in O O O O
order O O O O
to O O O O
ascertain O O O O
what O O O O
is O O O O
happening O O O O
in O O O O
the O O O O
cell O O O O
it O O O O
requires O O O O
information O O O O
on O O O O
the O O O O
foreign O O O O
invaders. O O O O
This O O O O
task O O O O
is O O O O
assumed O O O O
by O O O O
so-called O O O O
immunoproteasomes. O O O O
These O O O O
are O O O O
cylindrical O O O O
protein O O O O
complexes O O O O
that O O O O
break O O O O
down O O O O
the O O O O
protein O O O O
structures O O O O
of O O O O
the O O O O
intruders O O O O
into O O O O
fragments O O O O
that O O O O
can O O O O
be O O O O
used O O O O
by O O O O
the O O O O
defense O O O O
system. O O O O
"In O O O O
autoimmune O O O O
disorders O O O O
like O O O O
rheumatism, O O O O
type O O O O
1 O O O O
diabetes O O O O
and O O O O
multiple O O O O
sclerosis O O O O
or O O O O
severe O O O O
inflammations O O O O
a O O O O
significantly O O O O
increased O O O O
immunoproteasome O O O O
concentration O O O O
can O O O O
be O O O O
measured O O O O
in O O O O
the O O O O
cells," O O O O
explains O O O O
Prof. O O O O
Michael O O O O
Groll O O O O
at O O O O
the O O O O
TUM O O O O
Department O O O O
of O O O O
Biochemistry. O O O O
"The O O O O
deactivation O O O O
of O O O O
this O O O O
degradation O O O O
machinery O O O O
suppresses O O O O
the O O O O
regeneration O O O O
of O O O O
immune O O O O
signaling O O O O
molecules, O O O O
which, O O O O
in O O O O
turn, O O O O
prevents O O O O
an O O O O
excessive O O O O
immune O O O O
reaction." O O O O
Subtle Reason 3 O O
but Reason 3 O O
significant Reason 3 O O
differences Reason 3 O O
For Reason 3 O O
some Reason 3 O O
time Reason 3 O O
now, Reason 3 O O
scientists Reason 3 O O
have Reason 3 O O
been Reason 3 O O
on Reason 3 O O
the Reason 3 O O
lookout Reason 3 O O
for Reason 3 O O
new Reason 3 O O
active Reason 3 O O
substances Reason 3 O O
that Reason 3 O O
block Reason 3 O O
immunoproteasomes Reason 3 O O
in Reason 3 O O
a Reason 3 O O
targeted Reason 3 O O
manner Reason 3 O O
without Reason 3 O O
inhibiting Reason 3 O O
the Reason 3 O O
constitutive Reason 3 O O
proteasomes Reason 3 O O
also Reason 3 O O
present Reason 3 O O
in Reason 3 O O
cells. Reason 3 O O
Constitutive Reason 3 O O
proteasomes Reason 3 O O
break Reason 3 O O
down Reason 3 O O
defective Reason 3 O O
or Reason 3 O O
no Reason 3 O O
longer Reason 3 O O
required Reason 3 O O
proteins Reason 3 O O
and Reason 3 O O
are Reason 3 O O
thus Reason 3 O O
responsible Reason 3 O O
for Reason 3 O O
cellular Reason 3 O O
recycling. Reason 3 O O
Notably Reason 3 O O
cell Reason 3 O O
death Reason 3 O O
occurs, Reason 3 O O
when Reason 3 O O
both Reason 3 O O
the Reason 3 O O
constitutive Reason 3 O O
proteasomes Reason 3 O O
and Reason 3 O O
the Reason 3 O O
immunoproteasomes Reason 3 O O
are Reason 3 O O
inactivated. Reason 3 O O
In Reason 3 O O
early Reason 3 O O
2012 Reason 3 O O
the Reason 3 O O
research Reason 3 O O
team Reason 3 O O
led Reason 3 O O
by Reason 3 O O
Groll Reason 3 O O
fulfilled Reason 3 O O
a Reason 3 O O
prerequisite Reason 3 O O
for Reason 3 O O
designing Reason 3 O O
specific Reason 3 O O
active Reason 3 O O
substances: Reason 3 O O
They Reason 3 O O
solved Reason 3 O O
the Reason 3 O O
crystal Reason 3 O O
structure Reason 3 O O
of Reason 3 O O
the Reason 3 O O
immunoproteasome, Reason 3 O O
allowing Reason 3 O O
them Reason 3 O O
to Reason 3 O O
spot Reason 3 O O
the Reason 3 O O
subtle Reason 3 O O
but Reason 3 O O
significant Reason 3 O O
differences Reason 3 O O
between Reason 3 O O
the Reason 3 O O
otherwise Reason 3 O O
nearly Reason 3 O O
identical Reason 3 O O
structures. Reason 3 O O
Special O O O O
mode O O O O
of O O O O
action O O O O
The O O O O
potential O O O O
drug O O O O
that O O O O
the O O O O
researchers O O O O
developed O O O O
is O O O O
based O O O O
on O O O O
the O O O O
epoxyketon O O O O
ONX O O O O
0914, O O O O
an O O O O
immunoproteasome O O O O
inhibitor O O O O
that O O O O
is O O O O
undergoing O O O O
clinical O O O O
trials. O O O O
The O O O O
researchers O O O O
replaced O O O O
the O O O O
epoxyketon O O O O
with O O O O
a O O O O
sulfonyflouride O O O O
group O O O O
and O O O O
modified O O O O
its O O O O
positioning O O O O
on O O O O
the O O O O
inhibitor. O O O O
The O O O O
result O O O O
was O O O O
a O O O O
new O O O O
compound O O O O
that O O O O
selectively O O O O
inhibits O O O O
the O O O O
immunoproteasome O O O O
without O O O O
influencing O O O O
the O O O O
constitutive O O O O
proteasome. O O O O
First Reason 4 O O
author Reason 4 O O
Christian Reason 4 O O
Dubiella Reason 4 O O
explains Reason 4 O O
what Reason 4 O O
makes Reason 4 O O
the Reason 4 O O
discovered Reason 4 O O
mechanism Reason 4 O O
so Reason 4 O O
special: Reason 4 O O
"Normally Reason 4 O O
inhibitors Reason 4 O O
clog Reason 4 O O
up Reason 4 O O
the Reason 4 O O
active Reason 4 O O
center Reason 4 O O
of Reason 4 O O
the Reason 4 O O
enzyme Reason 4 O O
and Reason 4 O O
thereby Reason 4 O O
disable Reason 4 O O
its Reason 4 O O
functionality. Reason 4 O O
The Reason 4 O O
substance Reason 4 O O
synthesized Reason 4 O O
by Reason 4 O O
us, Reason 4 O O
however, Reason 4 O O
attaches Reason 4 O O
to Reason 4 O O
its Reason 4 O O
target, Reason 4 O O
causing Reason 4 O O
the Reason 4 O O
active Reason 4 O O
center Reason 4 O O
to Reason 4 O O
destroy Reason 4 O O
itself, Reason 4 O O
and Reason 4 O O
then Reason 4 O O
gets Reason 4 O O
detached Reason 4 O O
after Reason 4 O O
successful Reason 4 O O
inactivation." Reason 4 O O
Especially O O O O
the O O O O
insights O O O O
into O O O O
the O O O O
atomic O O O O
mechanisms O O O O
that O O O O
were O O O O
uncovered O O O O
using O O O O
X-ray O O O O
structure O O O O
analysis O O O O
open O O O O
the O O O O
door O O O O
to O O O O
the O O O O
custom-tailored O O O O
development O O O O
of O O O O
immunoprotease O O O O
inhibitors. O O O O
This O O O O
may O O O O
pave O O O O
the O O O O
road O O O O
for O O O O
a O O O O
future O O O O
generation O O O O
of O O O O
medications. O O O O
Story O O O O
Source: O O O O
[Materials](http://www.tum.de/en/about-tum/news/press-releases/short/article/31788/) O O O O
provided O O O O
by O O O O
[Technische O O O O
Universitaet O O O O
Muenchen](http://www.tum.de/en/homepage/). O O O O
Note: O O O O
Content O O O O
may O O O O
be O O O O
edited O O O O
for O O O O
style O O O O
